Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Canasa

×

Overview

What is Canasa?

The active ingredient in CANASA 1000 mg suppositories is mesalamine, also known as mesalazine or 5-aminosalicylic acid (5-ASA). Chemically, mesalamine is 5-amino-2-hydroxybenzoic acid, and is classified as an anti-inflammatory drug.

The empirical formula is CHNO, representing a molecular weight of 153.14. The structural formula is:

Each CANASA rectal suppository contains 1000 mg of mesalamine (USP) in a base of Hard Fat, NF.



What does Canasa look like?



What are the available doses of Canasa?

Sorry No records found.

What should I talk to my health care provider before I take Canasa?

Sorry No records found

How should I use Canasa?

CANASA 1000 mg Suppositories are indicated for the treatment of active ulcerative proctitis.

The usual dosage of CANASA (mesalamine, USP) 1000 mg suppositories is one rectal suppository 1 time daily at bedtime.

The suppository should be retained for one to three hours or longer, if possible, to achieve the maximum benefit. While the effect of CANASA suppositories may be seen within three to twenty-one days, the usual course of therapy would be from three to six weeks depending on symptoms and sigmoidoscopic findings. Studies have suggested that CANASA suppositories will delay relapse after the six-week short-term treatment.

NOTE: CANASA

suppositories will cause staining of direct contact surfaces, including but not limited to fabrics, flooring, painted surfaces, marble, granite, vinyl, and enamel.


What interacts with Canasa?

CANASA 1000 mg Suppositories are contraindicated in patients who have demonstrated hypersensitivity to mesalamine (5-aminosalicylic acid) or to the suppository vehicle [saturated vegetable fatty acid esters (Hard Fat, NF)], or to salicylates (including aspirin).



What are the warnings of Canasa?

Sorry No Records found


What are the precautions of Canasa?

Mesalamine has been implicated in the production of an acute intolerance syndrome characterized by cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache and a rash; in such cases prompt withdrawal is required. The patient’s history of sulfasalazine intolerance, if any, should be re-evaluated. If a rechallenge is performed later in order to validate the hypersensitivity, it should be carried out under close supervision and only if clearly needed, giving consideration to reduced dosage. In the literature, one patient previously sensitive to sulfasalazine was rechallenged with 400 mg oral mesalamine; within eight hours she experienced headache, fever, intensive abdominal colic, profuse diarrhea and was readmitted as an emergency. She responded poorly to steroid therapy and two weeks later a pancolectomy was required. The possibility of increased absorption of mesalamine and concomitant renal tubular damage as noted in the preclinical studies must be kept in mind. Patients on CANASA 1000 mg, especially those on concurrent oral products which contain or release mesalamine and those with pre-existing renal disease, should be carefully monitored with urinalysis, BUN and creatinine testing.

In a clinical trial most patients who were hypersensitive to sulfasalazine were able to take mesalamine enemas without evidence of any allergic reaction. Nevertheless, caution should be exercised when mesalamine is initially used in patients known to be allergic to sulfasalazine. These patients should be instructed to discontinue therapy if signs of rash or fever become apparent.

A small proportion of patients have developed pancolitis while using mesalamine. However, extension of upper disease boundary and/or flare-ups occurred less often in the mesalamine-treated group than in the placebo-treated group.

Rare instances of pericarditis have been reported with mesalamine containing products including sulfasalazine. Cases of pericarditis have also been reported as manifestations of inflammatory bowel disease. In the cases reported there have been positive rechallenges with mesalamine or mesalamine containing products. In one of these cases, however, a second rechallenge with sulfasalazine was negative throughout a 2 month follow-up. Chest pain or dyspnea in patients treated with mesalamine should be investigated with this information in mind. Discontinuation of CANASA suppositories may be warranted in some cases, but rechallenge with mesalamine can be performed under careful clinical observation should the continued therapeutic need for mesalamine be present.

There have been two reports in the literature of additional serious adverse events: one patient who developed leukopenia and thrombocytopenia after seven months of treatment with one 500 mg suppository nightly, and one patient with rash and fever which was a similar reaction to sulfasalazine.

See printed at the end of this insert.

Mesalamine caused no increase in the incidence of neoplastic lesions over controls in a two-year study of Wistar rats fed up to 320 mg/kg/day of mesalamine admixed with diet (about 1.7 times the recommended human intra-rectal dose, based on body surface area).

Mesalamine was not mutagenic in the Ames test, the mouse lymphoma cell (TK) forward mutation test, or the mouse micronucleus test.

No effects on fertility or reproductive performance of the male and female rats were observed at oral mesalamine doses up to 320 mg/kg/day (about 1.7 times the recommended human intra-rectal dose, based on body surface area). The oligospermia and infertility in men associated with sulfasalazine have not been reported with mesalamine.

Teratology studies have been performed in rats at oral doses up to 320 mg/kg/day (about 1.7 times the recommended human intra-rectal dose, based on body surface area) and in rabbits at oral doses up to 495 mg/kg/day (about 5.4 times the recommended human intra-rectal dose, based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to mesalamine. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed.

It is not known whether mesalamine or its metabolite(s) are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CANASA 1000 mg suppositories are administered to a nursing woman.

Safety and effectiveness in pediatric patients have not been established.

Clinical studies of CANASA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Mesalamine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function.


What are the side effects of Canasa?

The most frequent adverse reactions observed in the double-blind, placebo-controlled trials are summarized in the Table below.

In the multicenter, open-label, randomized, parallel group study comparing the CANASA 1000 mg suppository (HS) to that of the CANASA 500 mg suppository (BID), there were no differences between the two treatment groups in the adverse event profile. The most frequent AEs were headache (14.4%), flatulence (5.2%), abdominal pain (5.2%), diarrhea (3.1%), and nausea (3.1%). Three (3) patients had to discontinue medication because of a treatment emergent AE; one of these AEs (headache) was deemed possibly related to study medication.

In addition to the events observed in the clinical trials, the following adverse events have been associated with mesalamine containing products: nephrotoxicity, pancreatitis, fibrosing alveolitis and elevated liver enzymes. Cases of pancreatitis and fibrosing alveolitis have been reported as manifestations of inflammatory bowel disease as well.

Mild hair loss characterized by “more hair in the comb” but no withdrawal from clinical trials has been observed in seven of 815 mesalamine patients but none of the placebo-treated patients. In the literature there are at least six additional patients with mild hair loss who received either mesalamine or sulfasalazine. Retreatment is not always associated with repeated hair loss.

ADVERSE REACTIONS OCCURRING IN MORE THAN 1% OF MESALAMINE SUPPOSITORY TREATED PATIENTS (COMPARISON TO PLACEBO)
SymptomMesalaminePlacebo
N%N%
Dizziness53.022.4
Rectal Pain31.800.0
Fever21.200.0
Rash21.200.0
Acne21.200.0
Colitis21.200.0



What should I look out for while using Canasa?

CANASA 1000 mg Suppositories are contraindicated in patients who have demonstrated hypersensitivity to mesalamine (5-aminosalicylic acid) or to the suppository vehicle [saturated vegetable fatty acid esters (Hard Fat, NF)], or to salicylates (including aspirin).


What might happen if I take too much Canasa?

There have been no documented reports of serious toxicity in man resulting from massive overdosing with mesalamine. Under ordinary circumstances, mesalamine absorption from the colon is limited.


How should I store and handle Canasa?

Store between 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).Do not refrigerate. Keep the bottle in the outer carton when not in use.The product should be used within three months after it has been opened.Store between 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).Do not refrigerate. Keep the bottle in the outer carton when not in use.The product should be used within three months after it has been opened.Store between 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).Do not refrigerate. Keep the bottle in the outer carton when not in use.The product should be used within three months after it has been opened.CANASA (Mesalamine, USP) 1000 mg Suppositories: CANASAStore below 25°C (77°F), do not freeze. Keep away from direct heat, light or humidity.Rx onlyAxcan Pharma US, Inc.Birmingham, AL 35242Date: May 2008Relabeling of "Additional Barcode Label"  by:CANASA (Mesalamine, USP) 1000 mg Suppositories: CANASAStore below 25°C (77°F), do not freeze. Keep away from direct heat, light or humidity.Rx onlyAxcan Pharma US, Inc.Birmingham, AL 35242Date: May 2008Relabeling of "Additional Barcode Label"  by:CANASA (Mesalamine, USP) 1000 mg Suppositories: CANASAStore below 25°C (77°F), do not freeze. Keep away from direct heat, light or humidity.Rx onlyAxcan Pharma US, Inc.Birmingham, AL 35242Date: May 2008Relabeling of "Additional Barcode Label"  by:CANASA (Mesalamine, USP) 1000 mg Suppositories: CANASAStore below 25°C (77°F), do not freeze. Keep away from direct heat, light or humidity.Rx onlyAxcan Pharma US, Inc.Birmingham, AL 35242Date: May 2008Relabeling of "Additional Barcode Label"  by:CANASA (Mesalamine, USP) 1000 mg Suppositories: CANASAStore below 25°C (77°F), do not freeze. Keep away from direct heat, light or humidity.Rx onlyAxcan Pharma US, Inc.Birmingham, AL 35242Date: May 2008Relabeling of "Additional Barcode Label"  by:CANASA (Mesalamine, USP) 1000 mg Suppositories: CANASAStore below 25°C (77°F), do not freeze. Keep away from direct heat, light or humidity.Rx onlyAxcan Pharma US, Inc.Birmingham, AL 35242Date: May 2008Relabeling of "Additional Barcode Label"  by:CANASA (Mesalamine, USP) 1000 mg Suppositories: CANASAStore below 25°C (77°F), do not freeze. Keep away from direct heat, light or humidity.Rx onlyAxcan Pharma US, Inc.Birmingham, AL 35242Date: May 2008Relabeling of "Additional Barcode Label"  by:CANASA (Mesalamine, USP) 1000 mg Suppositories: CANASAStore below 25°C (77°F), do not freeze. Keep away from direct heat, light or humidity.Rx onlyAxcan Pharma US, Inc.Birmingham, AL 35242Date: May 2008Relabeling of "Additional Barcode Label"  by: